Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

890898P

Avanti

DOTMA

Avanti Research™ - A Croda Brand

Sinonimo/i:

1,2-di-O-octadecenyl-3-trimethylammonium propane (chloride salt)

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C42H84ClNO2
Numero CAS:
104872-42-6
Peso molecolare:
670.57
Numero MDL:
MFCD00145456
Codice UNSPSC:
12352211
NACRES:
NA.25

Stato

powder

Confezionamento

pkg of 2 × 100 mg (890898P-200mg)
pkg of 1 × 25 mg (890898P-25mg)

Produttore/marchio commerciale

Avanti Research™ - A Croda Brand

applicazioni

advanced drug delivery

Tipo di lipide

cationic lipids
transfection

Condizioni di spedizione

dry ice

Temperatura di conservazione

−20°C

Stringa SMILE

[H]C(C[N+](C)(C)C)(OCCCCCCCC/C=C\CCCCCCCC)COCCCCCCCC/C=C\CCCCCCCC.[Cl-]

InChI

LDGWQMRUWMSZIU-LQDDAWAPSA-M

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Applicazioni

DOTMA is suitable for use as a building block of miRNA delivery system and in the preparation.

Azioni biochim/fisiol

DOTMA is a cationic lipid, used as a non-viral vector for gene therapy. It exhibits effective in vitro and in vivo gene transfection. DOTMA induces a positive charge on the liposomes and thus promotes efficient liposome - cell membrane interaction.

Confezionamento

5 mL Clear Glass Sealed Ampule (890898P-200mg)
5 mL Clear Glass Sealed Ampule (890898P-25mg)

Note legali

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Codice della classe di stoccaggio

11 - Combustible Solids

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 10

1 of 10

18:1 TAP (DOTAP) Avanti Research™ - A Croda Brand

Avanti

890890C

18:1 TAP (DOTAP)

1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine ≥99.0% (10 mg phospholipid per ml CHCl3, TLC)

Sigma-Aldrich

42490

1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine

DC-Cholesterol HCl Avanti Research™ - A Croda Brand 700001P, powder

Avanti

700001P

DC-Cholesterol HCl

3-(Dimethylamino)-1,2-propanediol 98%

Sigma-Aldrich

210218

3-(Dimethylamino)-1,2-propanediol

GL67 Avanti Research™ - A Croda Brand

Avanti

890893P

GL67

18:0 DDAB Avanti Research™ - A Croda Brand

Avanti

890810P

18:0 DDAB

L-α-Phosphatidylethanolamine, dioleoyl ≥99% (GC), ≥98% (TLC), lyophilized powder

Sigma-Aldrich

P1223

L-α-Phosphatidylethanolamine, dioleoyl

18:1 DAP Avanti Research™ - A Croda Brand 890850C

Avanti

890850C

18:1 DAP

1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine ≥97.0% (TLC)

Sigma-Aldrich

76548

1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine

DMG-PEG 2000 Avanti Research™ - A Croda Brand

Avanti

880151P

DMG-PEG 2000

The use of cationic microbubbles to improve ultrasound-targeted gene delivery to the ischemic myocardium
Sun L, et al.
Biomaterials, 34(8), 2107-2116 (2013)
Yun Wu et al.
Molecular therapy. Nucleic acids, 2, e84-e84 (2013-04-18)
MicroRNA-29b (miR-29b) expression has been shown to be reduced in non-small-cell lung cancer (NSCLC) tissues. Here, we have identified the oncogene cyclin-dependent protein kinase 6 (CDK6) as a direct target of miR-29b in lung cancer. We hypothesized that in vivo
Jinhong Meng et al.
Scientific reports, 10(1), 1046-1046 (2020-01-25)
P53 mutations are responsible for drug-resistance of tumour cells which impacts on the efficacy of treatment. Alternative tumour suppressor pathways need to be explored to treat p53- deficient tumours. The E3 ubiquitin ligase, ITCH, negatively regulates the tumour suppressor protein
Jayesh A Kulkarni et al.
ACS nano, 12(5), 4787-4795 (2018-04-04)
Lipid nanoparticles (LNPs) containing short interfering RNA (LNP-siRNA) and optimized ionizable cationic lipids are now clinically validated systems for silencing disease-causing genes in hepatocytes following intravenous administration. However, the mechanism of formation and certain structural features of LNP-siRNA remain obscure.

Global Trade Item Number

SKUGTIN
890898P-200MG4061835188581
890898P-25MG4061835188598

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.